Bone and Renal Health in Infants With or Without Breastmilk Exposure to Tenofovir-Based Maternal Antiretroviral Treatment in the PROMISE Randomized Trial.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
15 08 2023
15 08 2023
Historique:
received:
12
10
2022
accepted:
03
04
2023
medline:
13
7
2023
pubmed:
18
5
2023
entrez:
18
5
2023
Statut:
ppublish
Résumé
We assessed bone and kidney outcomes in infants randomized postdelivery as mother-infant pairs within the IMPAACT PROMISE trial to maternal tenofovir disoproxil fumarate-based antiretroviral treatment (mART) or infant nevirapine prophylaxis (iNVP) to prevent breastfeeding HIV transmission. Infants were coenrolled in the P1084s substudy on randomization day and followed through Week 74. Lumbar spine bone mineral content (LS-BMC) was assessed at entry (6-21 age days) and Week 26 by dual-energy x-ray absorptiometry. Creatinine clearance (CrCl) was calculated at entry; Weeks 10, 26, and 74. Student t tests compared mean LS-BMC and CrCl at Week 26 and mean change from entry between arms. Of 400 enrolled infants, the mean (SD; n) for entry LS-BMC was 1.68 g (0.35; n = 363) and CrCl was 64.2 mL/min/1.73 m 2 (24.6; n = 357). At Week 26, 98% of infants were breastfeeding and 96% on their assigned HIV prevention strategy. The mean (SD) Week 26 LS-BMC was 2.64 g (0.48) for mART and 2.77 g (0.44) for iNVP; mean difference (95% confidence interval [CI]) -0.13 g (-0.22 to -0.04), P = 0.007, n = 375/398 (94%). Mean absolute (-0.14 g [-0.23 to -0.06]) and percent (-10.88% [-18.53 to -3.23]) increase in LS-BMC from entry was smaller for mART than iNVP. At Week 26, the mean (SD) CrCl was 130.0 mL/min/1.73 m 2 (34.9) for mART vs. 126.1 mL/min/1.73 m 2 (30.0) for iNVP; mean difference (95% CI) 3.8 (-3.0 to 10.7), P = 0.27, n = 349/398 (88%). Week 26 mean LS-BMC was lower in infants in the mART group compared with the iNVP group. However, this difference (∼0.23 g) was less than one-half SD, considered potentially clinically relevant. No infant renal safety concerns were observed.
Sections du résumé
BACKGROUND
We assessed bone and kidney outcomes in infants randomized postdelivery as mother-infant pairs within the IMPAACT PROMISE trial to maternal tenofovir disoproxil fumarate-based antiretroviral treatment (mART) or infant nevirapine prophylaxis (iNVP) to prevent breastfeeding HIV transmission.
METHODS
Infants were coenrolled in the P1084s substudy on randomization day and followed through Week 74. Lumbar spine bone mineral content (LS-BMC) was assessed at entry (6-21 age days) and Week 26 by dual-energy x-ray absorptiometry. Creatinine clearance (CrCl) was calculated at entry; Weeks 10, 26, and 74. Student t tests compared mean LS-BMC and CrCl at Week 26 and mean change from entry between arms.
RESULTS
Of 400 enrolled infants, the mean (SD; n) for entry LS-BMC was 1.68 g (0.35; n = 363) and CrCl was 64.2 mL/min/1.73 m 2 (24.6; n = 357). At Week 26, 98% of infants were breastfeeding and 96% on their assigned HIV prevention strategy. The mean (SD) Week 26 LS-BMC was 2.64 g (0.48) for mART and 2.77 g (0.44) for iNVP; mean difference (95% confidence interval [CI]) -0.13 g (-0.22 to -0.04), P = 0.007, n = 375/398 (94%). Mean absolute (-0.14 g [-0.23 to -0.06]) and percent (-10.88% [-18.53 to -3.23]) increase in LS-BMC from entry was smaller for mART than iNVP. At Week 26, the mean (SD) CrCl was 130.0 mL/min/1.73 m 2 (34.9) for mART vs. 126.1 mL/min/1.73 m 2 (30.0) for iNVP; mean difference (95% CI) 3.8 (-3.0 to 10.7), P = 0.27, n = 349/398 (88%).
CONCLUSION
Week 26 mean LS-BMC was lower in infants in the mART group compared with the iNVP group. However, this difference (∼0.23 g) was less than one-half SD, considered potentially clinically relevant. No infant renal safety concerns were observed.
Identifiants
pubmed: 37199427
doi: 10.1097/QAI.0000000000003218
pii: 00126334-202308150-00011
pmc: PMC10337310
mid: NIHMS1898370
doi:
Substances chimiques
Tenofovir
99YXE507IL
Anti-HIV Agents
0
Anti-Retroviral Agents
0
Nevirapine
99DK7FVK1H
Banques de données
ClinicalTrials.gov
['NCT01061151']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
431-437Subventions
Organisme : NICHD NIH HHS
ID : HHSN275201800001C
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068632
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069518
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068616
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069436
Pays : United States
Organisme : NICHD NIH HHS
ID : HHSN275201800001I
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI106716
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069436
Pays : United States
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no funding or conflicts of interest to disclose.
Références
J Pediatr. 2017 Feb;181:248-253.e3
pubmed: 27866821
AIDS. 2019 Dec 1;33(15):2403-2413
pubmed: 31764105
Clin Infect Dis. 2019 Jun 18;69(1):144-146
pubmed: 30924492
Clin Trials. 2020 Aug;17(4):437-447
pubmed: 32191142
Pediatr Infect Dis J. 2018 Nov;37(11):e264-e268
pubmed: 30067600
PLoS One. 2021 Feb 5;16(2):e0246272
pubmed: 33544759
Int J Infect Dis. 2019 Oct;87:8-12
pubmed: 31357055
PLoS One. 2021 Apr 29;16(4):e0250828
pubmed: 33914827
Pediatr Nephrol. 2012 Nov;27(11):2039-2048
pubmed: 22552885
Clin Infect Dis. 2015 Sep 15;61(6):996-1003
pubmed: 26060285
AIDS. 2020 Feb 1;34(2):215-225
pubmed: 31634154
J Hepatol. 2020 Jun;72(6):1082-1087
pubmed: 32044401
AIDS Res Treat. 2011;2011:354908
pubmed: 21716719
PLoS Med. 2016 Sep 27;13(9):e1002132
pubmed: 27676257
J Acquir Immune Defic Syndr. 2017 Sep 01;76(1):1-12
pubmed: 28291053
J Bone Miner Res. 2013 Jan;28(1):206-12
pubmed: 22887693
Pediatrics. 2006 Sep;118(3):e711-8
pubmed: 16923923
Hepatology. 2015 Aug;62(2):375-86
pubmed: 25851052
J Acquir Immune Defic Syndr. 2018 Apr 1;77(4):383-392
pubmed: 29239901
Curr Opin HIV AIDS. 2016 May;11(3):326-32
pubmed: 26859637
AIDS. 2009 Mar 27;23(6):689-96
pubmed: 19262355
Clin Infect Dis. 2009 Jun 1;48(11):e108-16
pubmed: 19400747
Clin Infect Dis. 2015 Jan 15;60(2):275-8
pubmed: 25313254
Eur J Clin Nutr. 2004 Feb;58(2):386-90
pubmed: 14749761
Am J Med. 2019 Aug;132(8):912-920
pubmed: 30853481
J Am Soc Nephrol. 2009 Mar;20(3):629-37
pubmed: 19158356
J Acquir Immune Defic Syndr. 2021 Jan 1;86(1):81-90
pubmed: 33027153
Aust Prescr. 2015 Oct;38(5):156-9
pubmed: 26648652
AIDS. 2019 Nov 15;33(14):2149-2156
pubmed: 31373919
AIDS Rev. 2016 Apr-Jun;18(2):59-68
pubmed: 27230467